Loading...
OTCM
SNZZF
Market cap44mUSD
Oct 14, Last price  
0.24USD
Name

Senzime AB (publ)

Chart & performance

D1W1MN
OTCM:SNZZF chart
P/E
—
P/S
3.52
EPS
—
Vol. 1Y
—
Shs. 5Y
20.88%
Rev. 5Y
61.95%
Div Yld LY
—
Div Yld TTM
—
Revenues
104m
+77.89%
000298,3431,235,019541,155152,6271,628,000189,0003,214,0006,711,0009,337,00010,980,00014,034,00035,754,00058,477,000104,022,000
Net income
-137m
L+15.74%
-1,721,470-2,354,674-2,100,326-4,392,512-5,597,835-6,191,678-7,580,563-9,412,000-13,027,000-25,621,000-33,675,000-47,445,000-82,143,000-132,700,000-134,149,000-118,727,000-137,419,000
CFO
-109m
L+2.98%
-1,603,309-2,119,541-1,950,783-6,063,884-5,429,576-3,847,443-6,413,380-10,004,000-12,292,000-17,733,000-27,135,000-38,335,000-81,328,000-136,778,000-113,908,000-105,938,000-109,097,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Uppsala, Sweden, Senzime AB (publ) is a medical technology company founded in 1999, specializing in the development and commercialization of advanced patient monitoring systems. These systems are designed to oversee individuals under anesthesia across a wide geographic reach, including Europe, Oceania, Asia, Canada, and the United States. A key offering is the TetraGraph monitor, which precisely stimulates, measures, analyzes, and displays muscle function for surgical patients administered neuromuscular blocking agents. The system includes the TetraSens electrode array, featuring two proximal stimulating electrodes for precise recording and reference. Its TetraConnect data management portal allows clinicians to easily access, view, and export records from the TetraGraph in PDF or Excel format. Additionally, TetraGraph Device Connectivity facilitates the transfer of data from the monitor to other patient monitoring systems. A specific TetraGraph Philips Interface enables the direct transmission of neuromuscular monitoring parameters (TOFC, TOFR, PTC, and TOF bars) to Philips patient monitors, displaying readings on the Philips Intellivue Monitor. The company's portfolio also includes the CliniSenz Analyzer, developed for continuous postoperative patient surveillance in hospital settings. Furthermore, the Onzurf Probe is a sterile, CE-marked, single-use micro-dialysis product that allows for continuous sampling from gastrointestinal organs like the esophagus, stomach, and liver. Senzime AB (publ) has entered into a strategic license and connectivity agreement with Masimo. This collaboration focuses on developing and commercializing the TetraGraph Smart Cable Module, designed to connect directly with Masimo's Root monitoring system and its digital hubs for seamless integration with hospital clinical information systems and electronic health records.

Key people

Philip Siberg
Chief Executive Officer · since 2024
Deputy Chairman of the Board · since 2023
Slavoljub Grujicic
Chief Financial Officer · since 2022
Johanna Tulkki
Chief Operating Officer, Executive Vice President · since 2024
Fredrik Norrby
Chief Technology Officer · since 2022
Anders Jacobson
Chief Scientific Officer · since 2024
G. W. Hamilton
Commercial Vice President - US · since 2023
Michael Noble
Vice President of Global Marketing · since 2024
Sorin Brull
Executive Director, Chief Medical Officer · since 2024
Johanna Faris
Head of Quality Assurance and Regulatory Affairs · since 2023
Lars Axelson
Director · since 2023
Goeran Brorsson
Independent Director · since 2023
Independent Director · since 2025
Independent Chairman of the Board · since 2023
IPO date
Jun 18, 2008
Employees
45
Domiciled in
SE
Incorporated in
SE
Headquarters & legal address
ULLS VÄG 41
Uppsala, C 756 51
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT